Google Play icon

Signature diagnosis

Posted February 3, 2016

Diagnosis and treatment decisions for a recently recognized type of children’s brain tumor should be improved by the discovery of the genetic mechanism that causes it, say researchers at Harvard Medical School and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center who identified the unusual DNA abnormality in angiocentric gliomas.

Cells from an angiocentric glioma. Image credit: Ligon lab.

Cells from an angiocentric glioma. Image credit: Ligon lab.

Currently there is no definitive pathological test to help identify this rare type of low-grade glioma. Named for their curious behavior of “hugging” blood vessels in the brain, angiocentric gliomas are usually cured with surgery and don’t need further treatment with radiation or chemotherapy. But given their recent description and difficulties in identifying them confidently, some patients receive the additional therapy, which often is damaging to the growing brain, in an effort to prevent a recurrence.

“Now we know these angiocentric gliomas have a different biology, and we have an exact way of identifying them so that patients can avoid this additional therapy that has life-long consequences,” said Rameen Beroukhim, HMS assistant professor of medicine at Dana-Farber Cancer Institute and a senior author of the report in Nature Genetics. Co-authors of the report include Keith Ligon, HMS associate professor of pathology at Dana-Farber/Boston Children’s, and Adam Resnick, an investigator at Children’s Hospital of Philadelphia.

Angiocentric gliomas were recognized as distinct entities less than 10 years ago. Their name reflects the tumor cells’ tendency to line up around blood vessels. Fewer than 30 cases have been described in medical literature. Seizures are typically the first symptom leading to diagnosis. Although they are classified as a tumor, they are not malignant and don’t spread to other parts of the body.

These rare tumors fall under the umbrella of pediatric low-grade gliomas (PLGG), which collectively are the most common pediatric brain tumor. Until now, no specific genetic abnormality had been identified as a “driver” of angiocentric gliomas.

In the current study, the researchers analyzed data from 249 PLGG tumors, including 19 angiocentric gliomas, and discovered an unusual genetic accident as the fundamental cause of the angiocentric gliomas. The culprit event is a shuffling of DNA segments that brings together two separate genes, MYB and QKI, which become joined, or fused. MYB is a “proto-oncogene,” a normal gene that can become a cancer-causing oncogene.  QKI is a tumor-suppressor gene that normally functions to prevent cells from becoming malignant.

When these two genes are abnormally joined, the researchers found, it triggers not one but the following three different mechanisms that converge to produce a tumor.

  • Epigenetic control elements called enhancers are “hijacked” and brought closer to the MYBgene, which increases MYB activity.
  • The MYB-QKI fusion gene causes cells to make a protein that binds to another control element—a promoter—that also revs up MYB activity, prodding the cells into runaway growth.
  • The rearrangement also knocks out one of the two copies of the QPI tumor suppressor gene, enabling cancer-related genes to escape control and contribute to tumor formation.

“This represents the first example of a single driver rearrangement simultaneously transforming cells via three genetic and epigenetic mechanisms in a cancer,” the authors wrote. They identified this specific abnormality as “a defining event” found only in the angiocentric gliomas—it was not present in any of the other pediatric low-grade gliomas examined in the study.

Because of these findings, the researchers said, angiocentric glioma should be classified as a separate biologic entity, with the presence of the gene fusion confirming the diagnosis. “This could aid in distinguishing angiocentric glioma from tumors with higher potential for recurrence that could require further treatment,” they said. The authors have developed the first genetic test now available for these patients through collaboration with cytogeneticist Azra Ligon, HMS associate professor of pathology at Brigham and Women’s Hospital and Dana-Farber.

Source: HMS

Featured news from related categories:

Technology Org App
Google Play icon
84,755 science & technology articles

Most Popular Articles

  1. Real Artificial Gravity for SpaceX Starship (September 17, 2019)
  2. Top NASA Manager Says the 2024 Moon Landing by Astronauts might not Happen (September 19, 2019)
  3. How social media altered the good parenting ideal (September 4, 2019)
  4. What's the difference between offensive and defensive hand grenades? (September 26, 2019)
  5. Just How Feasible is a Warp Drive? (September 25, 2019)

Follow us

Facebook   Twitter   Pinterest   Tumblr   RSS   Newsletter via Email